501.21MMarket Cap-1.28P/E (TTM)
8.340High7.330Low1.02MVolume8.180Open8.120Pre Close7.82MTurnover1.83%Turnover RatioLossP/E (Static)68.38MShares19.71052wk High-2.68P/B408.47MFloat Cap6.06552wk Low--Dividend TTM55.73MShs Float64.540Historical High--Div YieldTTM12.44%Amplitude5.840Historical Low7.692Avg Price1Lot Size
Phathom Pharmaceuticals Stock Forum
Joseph Stringer has given his Buy rating due to a combination of factors surrounding the recent developments at Phathom Pharmaceuticals. Stringer’s optimism is anchored in the approval of Voquezna for Non-Erosive GERD (NERD), a market considerably larger than the drug’s previous indications. This label expansion is expected to have ...
Associated w/ Non-Erosive GERD in Adults
» now approved for Non-Erosive GERD ✨
» demonstrated rapid heartburn relief in Ph3 trials
» represents the 1st major GERD innovation in 30 years
» the only FDA-approved Tx of its kind available 👏
No comment yet